TP53 and cancer: Targeting mutant TP53 has also been an attractive approach to modulate immune response in cancer immunotherapy, and TP53 and genes in its pathway are frequently mutated during the development of GBM (Shiraishi et al., 2002; Chasov et al., 2021).